ClinicalTrials.gg
RecruitingNCT07582861Updated Sep 10, 2026

Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD)

An interventional study of HeartGPS in Congenital Heart Disease (CHD), sponsored by Carelon Research. Recruiting at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Carelon Research · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Heart Defects, Congenital by Carelon Research — 2 open to participants now, 4 under way, 1 of them phase 3. Heart Defects, Congenital · Carelon Research.

Started
2026
with 1 other
No phase
5 of 10
2 open now
Registered
9th of 10
by date

Among the 10 studies in Heart Defects, Congenital by Carelon Research, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 9th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

2 of the 10 studies in Heart Defects, Congenital by Carelon Research are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Defects, Congenital by Carelon Research, or all of them as a file.
02

Study summary

This is a two-arm, prospective, longitudinal, randomized controlled trial (RCT) that will compare usual care to usual care plus a prenatally initiated, virtually administered psychological intervention, called HeartGPS.

Read the detailed description

This is a domain of the Building Optimal Strategies to Enhance Parent and Infant Wellbeing in CHD (BOND) platform trail. BOND is a randomized, multifactorial, adaptive platform trial that seeks to optimize parent wellbeing and infant development following prenatal or neonatal diagnosis of congenital heart disease (CHD). The primary objective of this domain is to determine the effects of a prenatally initiated, virtually administered mental health intervention, called HeartGPS, on maternal mental health and infant development following prenatal CHD diagnosis.

03

Conditions studied

  • Congenital Heart Disease (CHD)

Keywords

  • HeartGPS
  • CHD
  • intervention
  • Parent mental health
  • Neurodevelopment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Both mothers and infants are study participants.

Inclusion criteria

Inclusion Criteria:

  1. Pregnant individual carrying a fetus diagnosed with CHD or biological mother of an infant diagnosed with CHD in the neonatal period.
  2. Fetus or newborn with CHD anticipated to require cardiac surgery or transcatheter intervention in the first 30 days of life.
  3. CHD diagnosis received between 16.0 and 30.0 weeks gestation.
  4. Singleton pregnancy.
  5. Pregnant mother is planning to continue the pregnancy and pursue surgical or transcatheter intervention for the infant.

5. Pregnant mother is able to participate and complete study assessments in English or Spanish.

Exclusion criteria

Exclusion Criteria:

  1. Mother, fetal, or infant medical condition determined by a treating clinician to be contraindicative to study participation.
  2. Mother with a severe, untreated psychiatric condition, substance use disorder, or other circumstances that, in the opinion of the investigator, would interfere with engagement with study tasks or safe participation in the trial.
  3. Mother with a moderate to severe intellectual disability or is otherwise unable to provide .
  4. Postnatal diagnosis of CHD.
  5. Fetus with a comorbid condition with a predictable and major impact on neurodevelopment (e.g., Trisomy 21, DiGeorge syndrome).
  6. Pregnant individual is aged \<18 years.
  7. Pregnant individual is carrying a surrogate pregnancy.
  8. Consented mother completes \<70% of survey questions at first (baseline) assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • No intervention
    Usual Fetal Cardiac Care

    This is standard of care.

  • Experimental
    HeartGPS

    Usual Fetal Cardiac Care + HeartGPS intervention. GPS stands for Guiding parents through emotions, Providing information and support, and Strengthening connections. The HeartGPS intervention includes three key components tailored to the CHD population: 1. Eight virtually administered counseling sessions, 2. Tailored educational resource, 3. Mental health care plan.

    Other: HeartGPS

Interventions

  • OtherHeartGPS

    GPS stands for Guiding parents through emotions, Providing information and support, and Strengthening connections. Participants randomized to the treatment group will participate in HeartGPS, which includes three key components tailored to the CHD population: 1. Eight virtually administered counseling sessions, 2. Tailored educational resource, 3. Mental health care plan.

06

What researchers measure

Primary outcomes

  1. STAI - State total score at 4 months. Range is 20-80, with higher scores indicating higher levels of anxiety.

    State-Trait Anxiety Inventory (STAI) - State total score at 4 months

    Time frame: 4 months

Secondary outcomes

  1. STAI-State total score at 36 weeks gestation

    State-Trait Anxiety Inventory (STAI) - State total score at 36 weeks gestation. Range is 20-80, with higher scores indicating higher levels of anxiety.

    Time frame: 36 weeks gestation

  2. STAI-State total score at 1-2 months postpartum

    State-Trait Anxiety Inventory (STAI)-State total score at 1-2 months postpartum. Range is 20-80, with higher scores indicating higher levels of anxiety.

    Time frame: 1-2 months postpartum

  3. STAI-State total score at 12 months postpartum

    State-Trait Anxiety Inventory (STAI)-State total score at 12 months postpartum. Range is 20-80, with higher scores indicating higher levels of anxiety.

    Time frame: 12 months postpartum

  4. PCL-5 total score at 4 months

    PTSD Checklist for DSM-5 (PCL-5) total score at 4 months. Range is 0-80, with higher scores indicating greater symptom severity.

    Time frame: 4 months

  5. PCL-5 total score at 36 weeks gestation

    PTSD Checklist for DSM-5 (PCL-5) total score at 36 weeks gestation. Range is 0-80, with higher scores indicating greater symptom severity.

    Time frame: 36 weeks gestation

  6. PCL-5 total score at 1-2 months postpartum

    PTSD Checklist for DSM-5 (PCL-5) total score at 1-2 months postpartum. Range is 0-80, with higher scores indicating greater symptom severity.

    Time frame: 1-2 months postpartum

  7. PCL-5 total score at 12 months postpartum

    PTSD Checklist for DSM-5 (PCL-5) total score at 12 months postpartum. Range is 0-80, with higher scores indicating greater symptom severity.

    Time frame: 12 months postpartum

  8. BSID-4 at age 12 months

    Infant neurodevelopmental outcomes at age 12 months measured by Bayley Scales of Infant and Toddler Development, Fourth Edition (BSID-4). Scores are scaled (0-100) and interpreted as percentile ranks, with higher scores indicating better development. There are five composite domain scores - Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior - normed to mean 100 and SD 15, with higher scores indicating better development.

    Time frame: 12 months

  9. EDS total score at 4 months

    Maternal depressive symptoms at 4 months postpartum measured by the Edinburgh Depression Scale (EDS) total score. Range is 0-30, with higher scores indicating greater symptom severity.

    Time frame: 4 months

  10. EDS total score at 36 weeks gestation, 1-2 months postpartum, and 12 months

    Maternal depressive symptoms measured by the Edinburgh Depression Scale (EDS) total score. Range is 0-30, with higher scores indicating greater symptom severity.

    Time frame: 36 weeks gestation, 1-2 months postpartum, and 12 months

  11. CARE-Index at age 12 months

    Mother-infant interaction (dyadic synchrony) at 12 months measured by the Child-Adult Relationship Experimental Index (CARE-Index) at 12 months. The scores on these scales range from 0-14, with zero being dangerously insensitive, 7 being normally sensitive, and 14 being outstandingly sensitive.

    Time frame: 12 months

  12. PedsQL Infant Scales at age 12 months

    Pediatric Quality of Life (PedsQL) Infant Scales at 12 months. The scores range from 0 to 100, with higher scores indicating better quality of life

    Time frame: 12 months

  13. gestational age at birth infant clinical outcomes through 12 months. Infant clinical outcomes through 12 months

    gestational age at birth in weeks

    Time frame: birth

  14. birthweight infant clinical outcomes through 12 months. Infant clinical outcomes through 12 months

    weight at birth in kg

    Time frame: birth

  15. length of hospital stay through 12 months infant clinical outcomes through 12 months. Infant clinical outcomes through 12 months

    length of hospital stay through 12 months in days

    Time frame: birth through 12 months

  16. PTGI-SF at 12 months

    Post-traumatic Growth Inventory Short Form (PTGI-SF) at 12 months postpartum. T-scores are normed to mean 50 and SD 10, with higher scores indicating more posttraumatic growth.

    Time frame: 12 months postpartum

  17. Diurnal cortisol pattern at 32 weeks gestation

    Adaptive diurnal cortisol pattern as measured by Cortisol Area Under the Curve (AUCg) at 32 weeks gestation

    Time frame: 32 weeks gestation

07

Study locations

5 of 17 sites recruiting
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
    Recruiting
    • Principal Investigator · Contact
  • Lurie Children's Hospital
    Chicago, Illinois 60611, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Golisano Children's at UK
    Lexington, Kentucky 40502, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • University of Michigan Health System, Ann Arbor
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Principal Investigator · Contact
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Children's Hospital of New York
    New York, New York 10032, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
    • Principal Investigator · Contact
  • University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania 15213, United States
    Not yet recruiting
    • Principal Investigator · Contact
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Principal Investigator · Contact
  • Le Bonheur Children's Hospital
    Memphis, Tennessee 38103, United States
    Recruiting
    • Principal Investigator · Contact
  • Primary Children's Medical Center
    Salt Lake City, Utah 84113, United States
    Not yet recruiting
    • Principal Investigator · Contact
08

References and documents

Individual participant data

Plan to share: Yes — De-identified public use datasets with all study data will be created in accordance with NIH policy

Supporting information: Study protocol

Time frame: Data will be shared as soon as possible, but no later than the time of an associated publication or the end of the grant period, whichever comes first. Data will be available for as long as it is deemed useful for the larger research community, as directed by the PHN NHLBI project officers.

Access criteria: Creation of (free) login on PHN public website

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2029, 36 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 36 months is close to that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 13, 2026
StartActual
Jul 22, 2026
Primary completionEst.
Jul 2029
CompletionEst.
Aug 2030
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07582861
Lead sponsor
Carelon Research
Responsible party
Sponsor
First posted
May 13, 2026
Start date
Jul 22, 2026
Primary completion
Jul 2029 (estimated)
Completion
Aug 2030 (estimated)
Last update
Sep 10, 2026

Study contacts

Stephanie Lynch, MPH
Contact
stephanie.lynch@carelon.com
339-368-9294
Julie E Miller, MPH
Contact
julie.miller2@carelon.com
7812274645
Nadine Kasparian, PhD, PMH-C, FAHA
study chair · Cincinatti Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion